2,024 items · By date added

Citi: SK hynix profit rises again in the third quarter; Citi raises earnings forecasts

Higher memory prices and a greater share of high-value products drove a 38% quarter-on-quarter increase in SK hynix’s third-quarter operating profit. Citi raised its earnings forecasts for the fourth quarter and the following two years, while the company announced an annual shareholder return plan of approximately 100 trillion won.

Citi: BioNTech’s breast cancer trial meets its primary endpoint, but benefit is limited; Citi sees manageable impact on the stock

The phase III T-pam trial met its primary endpoint, but the progression-free survival benefit was limited and the incidence of interstitial lung disease was relatively high. Citi believes previously lowered expectations have softened the impact of the results on BioNTech, while also watching the endometrial cancer opportunity and other oncology programs.

A-share rebound gains volume: Robotics leads, with further gains dependent on continued funding

The ChiNext Index rose more than 3%, while turnover on the two mainland exchanges increased by 167.5 billion yuan from the previous trading day. The robotics theme drove a broader spread of first-time limit-up stocks, but follow-through in high-priced stocks was weak. The September rebound ended after volume contracted, making sustained turnover the key question this time.